newsfilter
← Earnings
Earnings Releases·

Keros Therapeutics — Third Quarter 2026 Earnings Summary

  • Reported net income of $14.2 million and revenue of $40.0 million for Q3 2026, representing a swing from a $7.3 million net loss and $14.3 million in revenue in the prior year period.
  • Net income per share improved to $0.71 (basic) from a $0.18 loss per share in Q3 2025, driven by Takeda license revenue and reduced R&D expenses for elritercept.
  • Cash and cash equivalents decreased to $259.5 million as of September 30, 2026, from $287.4 million at year-end 2025, with current funds projected to support operations through the second half of 2028.
  • Rinvatercept Phase 2 trial for Duchenne muscular dystrophy initiated in September 2026 with initial data expected in H1 2027, while KER-206 was nominated from the nonclinical pipeline for further investigation.
Company
KEROS THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology